ALLAKOS INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)

December 09, 2019 at 04:20 pm EST

font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

December 4, 2019

Allakos Inc.

(Exact name of registrant as specified in its charter)

Latest news about Allakos Inc.

North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	Mar. 15	DJ
Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Allakos Inc. Announces Publication Highlighting AK006 Mast Cell Inhibition	Feb. 12	CI
North American Morning Briefing : TSMC Results -2-	Jan. 18	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	Jan. 17	MT
Sector Update: Health Care	Jan. 17	MT
Top Midday Decliners	Jan. 17	MT
Allakos Shares Fall After Downgrades by Jefferies, Cantor Fitzgerald, Lifesci Capital	Jan. 17	MT
JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	Jan. 17	MT
Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	Jan. 17	MT
Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	Jan. 17	MT
Sector Update: Health Care Stocks Weaker Late Afternoon	Jan. 16	MT
Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	Jan. 16	MT
Lifesci Capital Downgrades Allakos to Market Perform From Outperform	Jan. 16	MT
Sector Update: Health Care Stocks Softer Tuesday Afternoon	Jan. 16	MT
Sector Update: Health Care	Jan. 16	MT
Allakos to Cut Workforce in Restructuring After Lirentelimab Trials Fail to Meet Targets; Shares Drop	Jan. 16	MT
Traders Digest More Bank Earnings, Fueling Narrow Premarket Losses for US Equity Futures	Jan. 16	MT
Transcript : Allakos Inc. - Special Call	Jan. 16
Allakos to stop further development of skin disease drug, plans job cuts	Jan. 16	RE
Allakos says experimental skin disease drug fails mid-stage studies	Jan. 16	RE
Allakos Announces Restructuring to Focus on Development of AK006	Jan. 16	CI
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints	Jan. 16	CI
North American Morning Briefing : S&P 500 Eyes -2-	Dec. 19	DJ

	1st Jan change	Capi.
ALLAKOS INC.	-63.00%	89.43M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.07%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

1st Jan change

Capi.

ALLAKOS INC.